{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","slug":"irccs-azienda-ospedaliero-universitaria-di-bologna","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Sequential therapy","genericName":"Sequential therapy","slug":"sequential-therapy","indication":"Other","status":"marketed"},{"name":"Tom-OX","genericName":"Tom-OX","slug":"tom-ox","indication":"Other","status":"phase_2"},{"name":"Metarapone","genericName":"Metarapone","slug":"metarapone","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"LMWH parnaparin subcutaneously","genericName":"LMWH parnaparin subcutaneously","slug":"lmwh-parnaparin-subcutaneously","indication":"Thromboembolism prophylaxis and treatment","status":"phase_3"},{"name":"Standardized antihypertensive therapy","genericName":"Standardized antihypertensive therapy","slug":"standardized-antihypertensive-therapy","indication":"Hypertension management","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Placebo + Tiotropium","genericName":"Placebo + Tiotropium","slug":"placebo-tiotropium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"Salbutamol + Tiotropium","genericName":"Salbutamol + Tiotropium","slug":"salbutamol-tiotropium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance and symptom relief","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Atezolizumab & Bevacizumab","genericName":"Atezolizumab & Bevacizumab","slug":"atezolizumab-bevacizumab","indication":"Hepatocellular carcinoma","status":"phase_3"}]}],"pipeline":[{"name":"LMWH parnaparin subcutaneously","genericName":"LMWH parnaparin subcutaneously","slug":"lmwh-parnaparin-subcutaneously","phase":"phase_3","mechanism":"Parnaparin is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","indications":["Thromboembolism prophylaxis and treatment","Deep vein thrombosis prevention and treatment","Pulmonary embolism prevention and treatment"],"catalyst":""},{"name":"Sequential therapy","genericName":"Sequential therapy","slug":"sequential-therapy","phase":"marketed","mechanism":"Sequential therapy refers to a treatment approach that administers multiple therapeutic agents in a planned sequence rather than simultaneously, optimizing efficacy and tolerability.","indications":[],"catalyst":""},{"name":"Standardized antihypertensive therapy","genericName":"Standardized antihypertensive therapy","slug":"standardized-antihypertensive-therapy","phase":"marketed","mechanism":"Standardized antihypertensive therapy reduces blood pressure through one or more established pharmacological classes of antihypertensive agents.","indications":["Hypertension management"],"catalyst":""},{"name":"Tom-OX","genericName":"Tom-OX","slug":"tom-ox","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atezolizumab & Bevacizumab","genericName":"Atezolizumab & Bevacizumab","slug":"atezolizumab-bevacizumab","phase":"phase_3","mechanism":"Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control.","indications":["Hepatocellular carcinoma","Advanced or metastatic non-small cell lung cancer","Renal cell carcinoma"],"catalyst":""},{"name":"Metarapone","genericName":"Metarapone","slug":"metarapone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo + Tiotropium","genericName":"Placebo + Tiotropium","slug":"placebo-tiotropium","phase":"marketed","mechanism":"Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic receptors in airway smooth muscle to produce sustained bronchodilation.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma (in combination with inhaled corticosteroids)"],"catalyst":""},{"name":"Salbutamol + Tiotropium","genericName":"Salbutamol + Tiotropium","slug":"salbutamol-tiotropium","phase":"marketed","mechanism":"Salbutamol is a short-acting beta-2 agonist that rapidly opens airways, while tiotropium is a long-acting anticholinergic that provides sustained bronchodilation for chronic airway obstruction.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance and symptom relief","Asthma maintenance and acute symptom relief"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE02bTAtb2pFaUdueFhUbEZQVDk1TmN1aG52LXhQNWFzTEJhYUM1Z1l4NDRpRWNaZjFicFBaX1lNTlk3cjMwNkhzSS1JZUtGQi1CS0dVellEdl9DVGFuaGpJ?oc=5","date":"2025-12-17","type":"pipeline","source":"nature.com","summary":"Performance and clinical utility of two targeted multigene panels for GIST molecular characterization - nature.com","headline":"Performance and clinical utility of two targeted multigene panels for GIST molecular characterization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5ka1V5Z0lZZGVpTTNxdW5ER1dXNzFBYmFDMmJ4TFJHNXYxUnFROUhxN19EN0lnbFNUbzdpTlRrVlFsWXh6NlFUNmE2WHdlcThTdng4QVJrSXc5dmpXa0RJ?oc=5","date":"2025-12-03","type":"pipeline","source":"nature.com","summary":"Distinct functional and compositional properties in the gut microbiome of children with acute lymphoblastic leukaemia identified by shotgun metagenomics | Scientific Reports - nature.com","headline":"Distinct functional and compositional properties in the gut microbiome of children with acute lymphoblastic leukaemia id","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE85WmszRnRxSjZYZXE5T3d0b19EQ0p3ZV8zYVRJbzRZM1JOZ3hWOFR2QV9FRThnTm5GUzY5OUxicGd6QjFfSFliUjhXam9vLXB4WnAyNU5Zam94OXd2REFz?oc=5","date":"2025-11-21","type":"pipeline","source":"nature.com","summary":"MiRNome alterations drive the malignant transformation of endometriosis into endometriosis-correlated ovarian cancer - nature.com","headline":"MiRNome alterations drive the malignant transformation of endometriosis into endometriosis-correlated ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-30","type":"regulatory","source":"European Medical Journal","summary":"A 6-Month, Single-Arm, Open-Label Clinical Study of the Effects of a Topical Solution Containing Urea, Lactic Acid, and Thymus vulgaris Leaf Oil, Used in the Treatment of Distal Lateral Subungual Onyc","headline":"A 6-Month, Single-Arm, Open-Label Clinical Study of the Effects of a Topical Solution Containing Urea, Lactic Acid, and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA3V1J1X2doc3NYeklRYTJvend1Q1JaREp6THNTTVFOaGxOTVg4MFg5U0gxWUJZQzNrQnlCUjRyX1lKZzZzRTZWS2Z3dndvMmUxbmpQd0VjUVZXcnY4cUZv?oc=5","date":"2025-10-26","type":"pipeline","source":"nature.com","summary":"Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia | Blood Cancer Journal - nature.com","headline":"Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFBGNEVFdVRXRldmVzBKSjR5dVJwSlhTTWpzcVRoZWlMaldtdU9SNmZVT0xWbXZ5cHgzUkR3d3F6bzNfQWxlU2VlRTdsQzNJRDJqMzRjRlVqQkl6Tm81N3hUT1pjSQ?oc=5","date":"2025-09-23","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBiMlRlOG9EWHBSc2JYemFjUXBTcUE1OXc1M1dwWExYUUlLLUdsYlozZnJzRjYzR2xpcWVTMGJXQjg3NmxNYUh4UXpmVk9FUzJqa0FjWEdXLVEwSDUzLXl1WkZZTEJHR3A3R0RfVzVxcXZkcDB5?oc=5","date":"2025-08-21","type":"pipeline","source":"acsjournals.onlinelibrary.wiley.com","summary":"Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib - acsjournals.onlinelibrary.wiley.com","headline":"Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOMHg1Z180ZXFCQXFiV1c4cU5LMWd4UmstT0dtS3llMWJfeWFQZzh4Rk9xZHY4Y29HcTNLZ1JXY2QyYVExbWtkaXRwTnYtdlk1LUsySHEwa1JZMXJQcG1DMFk3b25Pb1lWY2Zrb1lpTFF4YTBqV1NWLVhkMUI5Z21fRFZPd2d2M3gyS0xLRTdOWmZraU5FU2k0ZE80d2NmY1RGTzBwWkVDT2RYU2ZkR3BWUmZCQ1VraW1YVXBxT2hZYzA?oc=5","date":"2024-09-11","type":"trial","source":"HealthDay","summary":"Real-Life Data Show Safety, Efficacy of Baricitinib for Severe Alopecia Areata - HealthDay","headline":"Real-Life Data Show Safety, Efficacy of Baricitinib for Severe Alopecia Areata","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNcy1DY3N3aUVCNnZLNWE4YjRhMjducTZjeHhTNXUwRlJIc2JwclpNZDB6TXV5NmhDUFNRSlhEdkRFU0tzeXFPTVR5aG9fcExyZk5PN01OTkprNWg1S3JTLXM3MW9HdUl2M3RZT2JpUEM5QjFCUExWRnN0cng2ZVd5UDE4Q2lDWk02M0d0TmdxZjc?oc=5","date":"2024-06-25","type":"pipeline","source":"Frontiers","summary":"The management of achondroplasia in Italy: results from a Delphi panel based on real-world experience - Frontiers","headline":"The management of achondroplasia in Italy: results from a Delphi panel based on real-world experience","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxORm02aC1JVDl0OXJZM18yeHo4bTZaclpONmpucXdtRExUaG1iUnpGZEIwYWo1cFktM0tuSUdFX0ZtSWtQYVRrbTFMaE5TaDhJVzFvbHV1UDI2NExQT0xIUnJ6ckZsX0VZSTB5eXh3SlpjOE1adXFNd2RiYm1kcVBMNzRzTzNjOXo2RWVJNmtJQ2tYekw0YTVZMzIzbjBwWTR3Z0ZDdXlMU21HX0w0V0tLOGNtbHVYOHI0MUxYQVRFcTdMT0lMMmJvVHpObEF6cmdGdV9NdWQzcw?oc=5","date":"2024-01-16","type":"pipeline","source":"Open Access Government","summary":"Hydrogen therapy for liver surgery: Current insights and future prospects in ischemia-reperfusion injury - Open Access Government","headline":"Hydrogen therapy for liver surgery: Current insights and future prospects in ischemia-reperfusion injury","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNYWtPZ3dEQTd4SUFrVlJ3T2dGNlpXMzdBa0dfeHM5TmRxZWd3Q2NKVDRSUEllQjVsVGpuVUYxdG9raTRHS1JFUXhId0ItR09Ob080VUVlQkFyTGVwX3F5YUZLVmpleXV5ZzhJX0ZnTWEtOUJYVkV2YzBrblppX1FXU2VfNjVJSWdXZ2hLMWVKMzRsVTBPM1hJd3NncHRZQQ?oc=5","date":"2022-01-21","type":"regulatory","source":"Hematology Advisor","summary":"Features and Treatment for Iron Overload in Patients With Myelodysplastic Syndrome - Hematology Advisor","headline":"Features and Treatment for Iron Overload in Patients With Myelodysplastic Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQOVRJal9PdjdodTFPZXZhbmNtV1hRSDQyczNMUDhHV2gzdk5aTkR5RzVjaDFFOE9mSGdEOUZYeEprYmg5ZUtvTXM0X1RUcVRSZUItSlFlX3hwOVQydzMtWWNKQ2FHNENKUkc4MmpUUlJ3eTlkRmdNSjRTM1ZXSFhZWm1wbVJLcVd2d1ZFSzk0YXB0UzNDamZ6NzZLYUt3RkZmTFpyUGU4ejFyUFl0Undialc2R1dUWUVwXzRF?oc=5","date":"2021-09-21","type":"pipeline","source":"Renal and Urology News","summary":"Denosumab Improves Bone Disease in Kidney Transplant Recipients - Renal and Urology News","headline":"Denosumab Improves Bone Disease in Kidney Transplant Recipients","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":2,"marketed":5,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}